JP2021510174A5 - - Google Patents

Info

Publication number
JP2021510174A5
JP2021510174A5 JP2020557124A JP2020557124A JP2021510174A5 JP 2021510174 A5 JP2021510174 A5 JP 2021510174A5 JP 2020557124 A JP2020557124 A JP 2020557124A JP 2020557124 A JP2020557124 A JP 2020557124A JP 2021510174 A5 JP2021510174 A5 JP 2021510174A5
Authority
JP
Japan
Prior art keywords
peptide
use according
interaction
seq
affects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020557124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510174A (ja
JP7511242B2 (ja
Filing date
Publication date
Priority claimed from US16/184,129 external-priority patent/US20190194290A1/en
Application filed filed Critical
Priority claimed from PCT/US2019/012425 external-priority patent/WO2019136307A1/en
Publication of JP2021510174A publication Critical patent/JP2021510174A/ja
Publication of JP2021510174A5 publication Critical patent/JP2021510174A5/ja
Priority to JP2024097199A priority Critical patent/JP2024123100A/ja
Application granted granted Critical
Publication of JP7511242B2 publication Critical patent/JP7511242B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020557124A 2018-01-05 2019-01-04 自己免疫関連疾患を治療するための治療用ペプチドおよび方法 Active JP7511242B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024097199A JP2024123100A (ja) 2018-01-05 2024-06-17 自己免疫関連疾患を治療するための治療用ペプチドおよび方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862614262P 2018-01-05 2018-01-05
US62/614,262 2018-01-05
US16/184,129 2018-11-08
US16/184,129 US20190194290A1 (en) 2010-10-19 2018-11-08 Methods for preventing, modulating and/or reducing cardiovascular disease
PCT/US2019/012425 WO2019136307A1 (en) 2018-01-05 2019-01-04 Therapeutic peptides and methods for treating autoimmune related disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024097199A Division JP2024123100A (ja) 2018-01-05 2024-06-17 自己免疫関連疾患を治療するための治療用ペプチドおよび方法

Publications (3)

Publication Number Publication Date
JP2021510174A JP2021510174A (ja) 2021-04-15
JP2021510174A5 true JP2021510174A5 (https=) 2023-06-19
JP7511242B2 JP7511242B2 (ja) 2024-07-05

Family

ID=67144298

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020557124A Active JP7511242B2 (ja) 2018-01-05 2019-01-04 自己免疫関連疾患を治療するための治療用ペプチドおよび方法
JP2024097199A Pending JP2024123100A (ja) 2018-01-05 2024-06-17 自己免疫関連疾患を治療するための治療用ペプチドおよび方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024097199A Pending JP2024123100A (ja) 2018-01-05 2024-06-17 自己免疫関連疾患を治療するための治療用ペプチドおよび方法

Country Status (9)

Country Link
EP (1) EP3735260B1 (https=)
JP (2) JP7511242B2 (https=)
CN (2) CN119157997A (https=)
AU (1) AU2019205328B2 (https=)
BR (1) BR112020013716A2 (https=)
CA (1) CA3086193A1 (https=)
MX (1) MX2020007081A (https=)
SG (1) SG11202006494VA (https=)
WO (1) WO2019136307A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
ES2957957T3 (es) 2010-10-19 2024-01-30 Op T Llc Péptidos para modular la actividad de linfocitos T y usos de los mismos
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
JP2022540731A (ja) * 2019-07-12 2022-09-16 オーピー-ティー エルエルシー ペプチドおよび疾患の治療方法
EP4135742A2 (en) * 2020-04-17 2023-02-22 Op-T Llc Bioactive peptides and methods of use thereof
WO2021231898A2 (en) * 2020-05-14 2021-11-18 Op-T Llc Nanoparticle compositions and uses thereof
WO2022036495A1 (en) * 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CN115807071B (zh) * 2022-09-02 2025-09-26 宁夏医科大学 检测试剂在制备2型糖尿病伴动脉粥样硬化诊断工具中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
WO2005006949A2 (en) * 2003-07-07 2005-01-27 Wagner David H Methods for predicting development of auto-immune diseases and treatment of same
US7449200B2 (en) * 2006-04-17 2008-11-11 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means
ES2957957T3 (es) * 2010-10-19 2024-01-30 Op T Llc Péptidos para modular la actividad de linfocitos T y usos de los mismos
JP6285923B2 (ja) * 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規VISTA−Igコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのVISTA−Igの使用
EP3123176A4 (en) * 2014-03-23 2018-04-25 The Regents of the University of Colorado Diagnosis of multiple sclerosis in human and animal subjects

Similar Documents

Publication Publication Date Title
JP2021510174A5 (https=)
JP2020183389A5 (https=)
JP2016516016A5 (https=)
RU2019100525A (ru) Векторная система на основе аденоассоциированного вируса
JP7759724B2 (ja) エルゴチオネイン、アスコルビン酸2-グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用
JP2020502151A5 (https=)
US20190038769A1 (en) Micro-rna profiling, compositions, and methods of treating diseases
JPH09508116A (ja) 末梢血単核細胞溶解活性を刺激するためのil−10の使用
JP7074300B2 (ja) ガバペンチノイドからの干渉が減少し、hgf異型体を発現するdnaコンストラクトを用いる神経病症の治療
US20170348393A1 (en) Treatment of cns inflammatory disorders
Fargnoli Secukinumab: The anti-IL-17A biologic for the treatment of psoriasis
Schmid et al. New strategies for managing anemia of chronic kidney disease
CN106138098B (zh) 自然杀伤细胞联合抗抑郁药在改善抑郁症状中的应用
CN116966302A (zh) Areg的新用途
CN115487292A (zh) 一种治疗糖尿病的联合用药物及其应用
TWI359030B (en) Treatment of cellular proliferative disorders
CN103656639B (zh) 不规则趋化因子的中和抗体用于制备消除糖尿病心肾功能损害不良代谢记忆的药物的用途
JP2018500882A5 (https=)
CN115813925B (zh) Acbi1的应用
US20130102662A1 (en) Use of inducible nitric oxide synthase inhibitors and nitric oxide scavengers to inhibit post-traumatic immunodepression
Butt et al. Abstract# 1394569: Efficacy and Safety of Empagliflozin: Real-World Tertiary Center Experience from the Kingdom of Saudi Arabia
Шапошников et al. INDICATORS OF IMMUNE STATUS AND REPRODUCTIVE FUNCTION OF HIGH YIELDING COWS AFTER APPLICATION OF AMINOSELEFERON-B
Bonner et al. 221. Staurosporine Increases Lentiviral Transduction of Human CD34+ Cells
CN119733056A (zh) 一种新型肿瘤微环境免疫调节剂及其用途
Perry HUMAN LEUKEMIA-AN OVERVIEW